CVE-2026-42933: Pronetiqs Panduit Intravue

Critical severity, CVSS 10.0. EPSS: 0.5% chance of exploitation in the next 30 days.

Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.

Affected products

• Pronetiqs Panduit Intravue: up to and including 3.2.1a14

Published 2026-07-23. Last modified 2026-07-27.